beta Amyloid 1-16 Polyclonal Antibody

Formalin-fixed and paraffin embedded rat hippocampus labeled with Anti-Beta-Amyloid (1-16) (Human) Polyclonal Antibody, Unconjugated (bs-0104M), followed by conjugation to the secondary antibody and DAB staining

$Human U87mg cells probed with beta amyloid 1-16 Polyclonal Antibody, unconjugated (bs-0104M) at 1:300 overnight at 4\u00b0C followed by a conjugated secondary antibody at 1:10000 for 90 minutes at 37\u00b0C.$

Human U87mg cells probed with beta amyloid 1-16 Polyclonal Antibody, unconjugated (bs-0104M) at 1:300 overnight at 4\u00b0C followed by a conjugated secondary antibody at 1:10000 for 90 minutes at 37\u00b0C.

$Lane 1: Human U87MG cell lysates; Lane 2: Human SY5Y cell lysates; Lane 3: Human U251 cell lysates probed with beta Amyloid 1-16 Polyclonal Antibody, Unconjugated (bs-0104M) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.$

Lane 1: Human U87MG cell lysates; Lane 2: Human SY5Y cell lysates; Lane 3: Human U251 cell lysates probed with beta Amyloid 1-16 Polyclonal Antibody, Unconjugated (bs-0104M) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

$Paraformaldehyde-fixed, paraffin embedded (rat brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with (beta Amyloid 1-16) Polyclonal Antibody, Unconjugated (bs-0104M) at 1:200 overnight at 4\u00b0C, followed by operating according to SP Kit(Mouse)(sp-0024) instructionsand DAB staining.$

Paraformaldehyde-fixed, paraffin embedded (rat brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with (beta Amyloid 1-16) Polyclonal Antibody, Unconjugated (bs-0104M) at 1:200 overnight at 4\u00b0C, followed by operating according to SP Kit(Mouse)(sp-0024) instructionsand DAB staining.

Applications

Reactivity

Human

Predicted Reactivity

Overview
Catalog #	bs-0104m
Product Name	beta Amyloid 1-16 Polyclonal Antibody
Applications	WB
Reactivity	Human
Predicted Reactivity	Pig
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	KLH conjugated synthetic peptide of human beta-Amyloid(1-16)
Immunogen Range	670-700/770
Clonality	Polyclonal
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	351
Swiss Prot	P05067
Subcellular location	Extracellular
Synonyms	AAA; AD1; PN2; ABPP; APPI; CVAP; ABETA; PN-II; CTFgamma; Amyloid beta A4 protein; APP; Alzheimer disease amyloid protein; Cerebral vascular amyloid peptide; PreA4; Protease nexin-II; A4
Background	Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1. Beta-amyloid peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Beta-amyloid 42 is a more effective reductant than beta-amyloid 40. Beta-amyloid peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. Beta-APP42 may activate mononuclear phagocytes in the brain and elicit inflammatory responses.
Application Dilution
WB	=1:500-2000